Hepatitis B and C virus infection among 1.2 million persons with access to care: Factors associated with testing and infection prevalence

Clinical Infectious Diseases

Volumn 55, Issue 8, 2012, Pages 1047-1055

  Spradling, Philip R ^a   Rupp, Loralee ^b   Moorman, Anne C ^a   Lu, Mei ^b   Teshale, Eyasu H ^a   Gordon, Stuart C ^b   Nakasato, Cynthia ^c   Boscarino, Joseph A ^d   Henkle, Emily M ^e   Nerenz, David R ^b   Denniston, Maxine M ^a   Holmberg, Scott D ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

^c KAISER PERMANENTE   (United States)

^d GEISINGER HEALTH SYSTEM   (United States)

^e CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE;

ADULT; AGED; ALASKA NATIVE; AMERICAN INDIAN; ASIAN; CAUCASIAN; COHORT ANALYSIS; FEMALE; FOLLOW UP; GROUPS BY AGE; HEALTH CARE ACCESS; HEALTH SURVEY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS VIRUS TESTING; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIVE HAWAIIAN; NEGRO; OBSERVATIONAL STUDY; PACIFIC ISLANDER; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; SERODIAGNOSIS; UNITED STATES; VIRUS DIAGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEPATITIS B; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREVALENCE; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84866667687     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis616     Document Type: Review

References (25)

1. IOM (Institute of Medicine). Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. Washington, DC: The National Academies Press, 2010.
2. Kim WR, Terrault NA, Pedersen RA, et al. Trends in waitlist registration for liver transplantation for viral hepatitis in the US. Gastroenterology 2009; 137:1680-6.
3. CDC. Viral hepatitis: statistics and surveillance, 2009. Available at: http://www.cdc.gov/hepatitis/Statistics.htm. Accessed 19 May 2011.
4. Hagan H, Campbell J, Thiede H, et al. Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Reports 2006; 121:710-9.
5. Lin SY, Chang ET, So SK. Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California. Hepatology 2007; 46:1034-40.
6. Kim WR. The dawn of a new era: transforming our domestic response to hepatitis B and C. Activity 6: reports from today's health care environment on the implementation of screening, diagnosis, and treatment recommendations. J Fam Pract (Supp) 2010; 59:S43-9.
7. Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut 2007; 56:385-9.
8. Rousseau CM, Ioannou GN, Todd-Stenberg JA, et al. Racial differences in the evaluation and treatment of hepatitis C among veterans: a retrospective cohort study. Am J Pub Health 2008; 98:846-52.
9. Trooskin SB, Navarro VJ, Winn RJ, et al. Hepatitis C risk assessment, testing, and referral for treatment in urban primary care: role of race and ethnicity. World J Gastroenetrol 2007; 13:1074-8.
10. Kanwal F, Schnitzler MS, Bacon BR, Hoang T, Buchanan PM, Asch SM. Quality of care in patients with chronic hepatitis C virus infection. Ann Intern Med 2010; 153:231-9.
11. Groom H, Dieperink E, Nelson DB, et al. . Outcomes of a hepatitis C screening program at a large urban VA medical center. J Clin Gastroenterol 2008; 42:97-106.
12. Ioannou GN. Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey. Ann Intern Med 2011; 154:319-28.
13. NCHS data brief number 27, March 2010, viral hepatitis. Available at: http://www.cdc.gov/nchs/data/databriefs. Accessed 5 June 2011.
14. Fleming DT, Zambrowski A, Fong F, et al. Surveillance programs for chronic viral hepatitis in three health departments. Public Health Rep 2006; 121:23-35.
15. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006; 28:112-25.
16. CDC. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR 2008; 57(RR-8):1-20.
17. CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998; 47(RR-19).
18. Alter MJ, Seeff LB, Bacon BR, Thomas DL, Rigsby MO, Di Bisceglie AM. Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Ann Intern Med 2004; 141:715-7.
19. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-74.
20. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999-2002. Ann Intern Med 2006; 144:705-14.
21. Arnold DT, Bentham LM, Jacob RP, Lilford RJ, Girling AJ. Should patients with abnormal liver function tests in primary care be tested for chronic viral hepatitis: cost minimization analysis based on a comprehensively tested cohort. BMC Family Practice 2011; 12:9.
22. Zapata R. Clinical approach to the patient with chronic hepatitis C infection and normal aminotransferases. Ann Hepatol 2010; 9 (Suppl):72-9.
23. Brillanti S, Foli M, Gaiani S, Masci C, Miglioli M, Barbara L. Persistent hepatitis C viraemia without liver disease. Lancet 1993; 341: 464-5.
24. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. Performance characteristics of laboratory tests. Clin Chem 2000; 46:2027-49.
25. Deuffic-Burban S, Yazdanpanah Y. It is time to change the paradigm for hepatitis C virus testing. Clin Infect Dis 2012; 54:1272-4.